Loading…
CIK 0002018299 • 9 13F filings • May 15, 2025 – Aug 14, 2026
Import this data to Google Sheets with:
=jivedata("boxer-capital-management-llc","13f")Uses this filer's slug. Install the Jive Data add-on first; the second argument is "13f".
Past 5 quarters
| % of Portfolio | |||||
|---|---|---|---|---|---|
| ABIVAX SA | SPONSORED ADS | $16.9M | 3.7%Prev: 3.2% | 125,000 SH | Increased+5,000 SH |
| AMYLYX PHARMACEUTICALS INC | COM | $9.7M | 2.1%Prev: 3.9% | 800,000 SH | Decreased-100,000 SH |
| APOGEE THERAPEUTICS INC | COM | $5.3M | 1.2%Prev: 0.6% | 70,000 SH | Increased+20,000 SH |
| AVALO THERAPEUTICS INC | COM NEW | $5.0M | 1.1%Prev: 0.5% | 275,000 SH | Increased+150,000 SH |
| CAPRICOR THERAPEUTICS INC | COM NEW | $9.4M | 2.1% | 325,000 SH | New |
| CELCUITY INC | COM | $22.4M | 4.9%Prev: 1.4% | 225,000 SH | Increased+135,000 SH |
| CIDARA THERAPEUTICS INC | COM NEW | $11.7M | 2.6%Prev: 1.5% | 53,000 SH | Increased+5,000 SH |
| CLENE INC | COM NEW | $1.2M | 0.3% | 199,737 SH | New |
| COGENT BIOSCIENCES INC | COM | $8.0M | 1.7% | 225,000 SH | New |
| CONTINEUM THERAPEUTICS INC | CL A | $5.6M | 1.2% | 494,000 SH | New |
| CRESCENT BIOPHARMA INC. | COM | $5.4M | 1.2%Prev: 1.7% | 453,686 SH | Decreased |
| CYBIN INC | COM NEW | $5.8M | 1.3% | 715,000 SH | New |
| CYTOKINETICS INC | COM NEW | $6.4M | 1.4%Prev: 3.5% | 100,000 SH | Decreased-100,000 SH |
| INOVIO PHARMACEUTICALS INC | COM SHS | $4.2M | 0.9%Prev: 1.7% | 2,420,122 SH | Decreased+120,122 SH |
| INVIVYD INC | COM | $3.7M | 0.8% | 1,500,000 SH | New |
| KALVISTA PHARMACEUTICALS INC | COM | $329K | 0.1%Prev: 0.1% | 20,400 SH | Increased |
| KARYOPHARM THERAPEUTICS INC | COM NEW | $1.9M | 0.4% | 252,536 SH | New |
| KODIAK SCIENCES INC | COM | $31.8M | 7.0%Prev: 3.9% | 1,136,000 SH | Increased+386,000 SH |
| KYMERA THERAPEUTICS INC | COM | $25.6M | 5.6%Prev: 5.8% | 329,100 SH | Increased+10,000 SH |
| LB PHARMACEUTICALS INC | COM SHS | $1.6M | 0.3%Prev: 0.4% | 70,000 SH | Increased |
| MILESTONE PHARMACEUTICALS IN | COM | $1.3M | 0.3%Prev: 0.4% | 666,666 SH | Increased |
| MIND MEDICINE MINDMED INC | COM NEW | $8.0M | 1.8%Prev: 0.6% | 598,500 SH | Increased+435,000 SH |
| MOONLAKE IMMUNOTHERAPEUTICS | CLASS A ORD | $3.6M | 0.8%Prev: 0.6% | 275,000 SH | Increased+25,000 SH |
| NURIX THERAPEUTICS INC | COM | $1.9M | 0.4%Prev: 0.5% | 100,000 SH | Increased-75,000 SH |
| NUVATION BIO INC | *W EXP 02/10/202 | $88K | 0.0%Prev: 0.0% | 266,666 SH | Increased |
| PALISADE BIO INC | COM | $11.3M | 2.5% | 4,799,875 SH | New |
| PEPGEN INC | COM | $2.4M | 0.5%Prev: 0.4% | 373,892 SH | Increased+123,892 SH |
| PRAXIS PRECISION MEDICINES I | COM NEW | $13.7M | 3.0% | 46,457 SH | New |
| PRECIGEN INC | COM | $5.7M | 1.3%Prev: 0.9% | 1,375,000 SH | Increased+525,000 SH |
| PROTAGONIST THERAPEUTICS INC | COM | $14.8M | 3.2%Prev: 2.3% | 170,000 SH | Increased+60,000 SH |
| PTC THERAPEUTICS INC | COM | $15.2M | 3.3%Prev: 3.9% | 200,000 SH | Increased |
| REPLIMUNE GROUP INC | COM | $7.3M | 1.6%Prev: 1.4% | 750,000 SH | Increased-300,000 SH |
| REVOLUTION MEDICINES INC | COM | $31.9M | 7.0%Prev: 6.0% | 400,000 SH | Increased |
| SAREPTA THERAPEUTICS INC | COM | $3.2M | 0.7%Prev: 1.5% | 150,000 SH | Decreased-100,000 SH |
| SOLID BIOSCIENCES INC | COM NEW | $1.7M | 0.4%Prev: 1.2% | 300,000 SH | Decreased-300,000 SH |
| STRUCTURE THERAPEUTICS INC | SPONSORED ADS | $5.2M | 1.1% | 75,000 SH | New |
| SURROZEN INC | *W EXP 08/01/203 | $1K | 0.0%Prev: 0.0% | 66,666 SH | Increased |
| SURROZEN INC | COM NEW | $9.4M | 2.1% | 416,150 SH | New |
| TANGO THERAPEUTICS INC | COM | $96.4M | 21.1%Prev: 26.2% | 10,876,219 SH | Increased+1,104,734 SH |
| TERNS PHARMACEUTICALS INC | COM | $15.2M | 3.3% | 375,000 SH | New |
| UNIQURE NV | SHS | $6.9M | 1.5%Prev: 14.9% | 290,000 SH | Decreased-510,000 SH |
| UPSTREAM BIO INC | COM | $4.1M | 0.9% | 150,000 SH | New |
| UROGEN PHARMA LTD | COM | $11.7M | 2.6%Prev: 3.7% | 500,000 SH | Increased-75,000 SH |
| VIR BIOTECHNOLOGY INC | COM | $3.8M | 0.8% | 625,000 SH | New |
| ZURA BIO LTD | CLASS A ORD SHS | $262K | 0.1% | 50,000 SH | New |
| 13F-HR |
| 0001213900-26-090024 |
| $1.33B |
| View |
| Feb 17, 2026 | Q2 2025 | 13F-HR/A | 0002018299-26-000004 | $198.7M | View |
| May 15, 2026 | Q1 2026 | 13F-HR | 0001213900-26-057335 | $761.7M | View |
| Feb 17, 2026 | Q1 2025 | 13F-HR/A | 0002018299-26-000003 | $332.5M | View |